XML 32 R19.htm IDEA: XBRL DOCUMENT v3.25.3
Stockholders' Equity
 9 Months Ended
Sep. 30, 2025
Equity [Abstract]  
Stockholders' Equity Stockholders’ Equity
The authorized shares of the Company consist of an unlimited number of common and preferred shares, both without par value. All proceeds received for issuances of common shares are attributed to common shares on the Company’s consolidated balance sheets.
During the three months ended September 30, 2025, the Company issued:
i)46,210 common shares on the exercise of stock options, for gross proceeds of $94. In connection with the stock options exercised, the Company reclassified $54 from additional paid in capital to common shares.
ii)The Company entered into four base capped call transactions with each of Deutsche Bank AG, London Branch, Nomura Global Financial Products Inc., Truist Bank and UBS AG, London Branch (together, the “Option Counterparties”), (together, the “Base Capped Call Transactions”). The Company also entered into an additional four capped call transactions with the Option Counterparties (together, the “Additional Capped Call Transactions” and, together with the Base Capped Call Transactions, the “Capped Call Transactions” or the “2030 Capped Calls”). The 2030 Capped Calls are generally intended to reduce or offset the potential economic dilution to the common shares upon conversion of the Company’s 5.5% Convertible Senior Notes due 2030 (the “Convertible Senior Notes”). As the 2030 Capped Calls are considered indexed to the Company’s own equity and are equity classified, they are recorded in shareholders’ equity and are not accounted for as a derivative. The costs of $11,549 incurred in connection with the 2030 Capped Calls were recorded as a reduction to additional paid-in capital. The Capped Calls Transactions are excluded from the calculation of diluted earnings per share, as they would be anti-dilutive under treasury stock method.
During the three months ended September 30, 2024, the Company issued:
i)757,250 common shares on the exercise of warrants, for gross proceeds of $1,864. In connection with the warrants exercised, the Company reclassified $614 from additional paid in capital to share capital.
ii)118,750 common shares on the exercise of stock options, for gross proceeds of $81. In connection with the stock options exercised, the Company reclassified $185 from additional paid in capital to common shares.
During the nine months ended September 30, 2025, the Company issued:
i)90,000 common shares on the exercise of warrants, for gross proceeds of $236. In connection with the warrants exercised, the Company reclassified $66 from additional paid in capital to share capital.
ii)899,586 common shares on the exercise of stock options, for gross proceeds of $784. In connection with the stock options exercised, the Company reclassified $598 from additional paid in capital to common shares.
iii)The Company entered into the Capped Call Transactions on August 20 and August 22, 2025. The 2030 Capped Calls are generally intended to reduce or offset the potential economic dilution to the common shares. As the 2030 Capped Calls are considered indexed to the Company’s own equity and are equity classified, they are recorded in shareholders’ equity and are not accounted for as a derivative. The costs of $11,549 incurred in connection with the 2030 Capped Calls were recorded as a reduction to additional paid-in capital. The Capped Calls Transactions are excluded from the calculation of diluted earnings per share, as they would be anti-dilutive under treasury stock method.

During the nine months ended September 30, 2024, the Company issued:
i)2,564,102 units to Boss in February of 2024, for a private placement at a price of $3.90 per unit for gross proceeds of $10,000.
ii)6,872,143 common shares to extinguish the convertible note with a carrying value of $23,117 in February 2024.
iii)8,224,985 common shares on the exercise of warrants, for gross proceeds of $23,918. In connection with the warrants exercised, the Company reclassified $7,454 from additional paid in capital to share capital.
iv)2,055,617 common shares on the exercise of stock options, for gross proceeds of $1,522. In connection with the stock options exercised, the Company reclassified $1,674 from additional paid in capital to common stock.
v)495,765 common shares sold in accordance with the Company’s ATM program for gross proceeds of $2,008.
Share Purchase Warrants
A summary of the status of the Company’s warrants as of September 30, 2025, and changes during the three months then ended is as follows:
Number of WarrantsWeighted Average Exercise Price (CAD)
Outstanding, December 31, 202419,934,084C$3.81
Exercised(90,000)3.75 
Expired(2,444)3.27 
Outstanding, September 30, 202519,841,640C$3.81
As of September 30, 2025, share purchase warrants outstanding were as follows:
Warrants Outstanding September 30, 2025
Warrant Price Per Share (CAD) Number of
Warrants		Weighted Average
Remaining Life
(years)		Weighted Average
Exercise Price
(CAD)
C$4.053,835,4400.07C$4.05
C$3.7516,006,2000.30C$3.75
Total19,841,6400.37C$3.81